Regencell Bioscience (NASDAQ:RGC) Shares Gap Up – Here’s What Happened

Shares of Regencell Bioscience Holdings Limited (NASDAQ:RGC) gapped up prior to trading on Friday . The stock had previously closed at $25.40, but opened at $26.78. Regencell Bioscience shares last traded at $25.1250, with a volume of 18,397 shares.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Regencell Bioscience currently has an average rating of “Sell”.

Regencell Bioscience Price Performance

The stock’s fifty day simple moving average is $26.92 and its two-hundred day simple moving average is $21.38.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its holdings in shares of Regencell Bioscience by 5,637.5% in the second quarter. Geode Capital Management LLC now owns 391,066 shares of the company’s stock valued at $6,664,000 after buying an additional 384,250 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Regencell Bioscience during the 2nd quarter worth $1,701,000. BNP Paribas Financial Markets bought a new stake in shares of Regencell Bioscience during the 2nd quarter worth $768,000. XTX Topco Ltd acquired a new position in shares of Regencell Bioscience in the 3rd quarter worth $598,000. Finally, Hudson Bay Capital Management LP acquired a new position in shares of Regencell Bioscience in the 4th quarter worth $275,000. Institutional investors and hedge funds own 0.13% of the company’s stock.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.